Clinical Trials for Liver Cancer

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls children, adolescents, and young adults with recurrent or refractory solid tumors (including lymphomas and desmoid tumors), treating them with intravenous tegavivint, a small molecule inhibitor targeting TBL1 to disrupt Wnt/beta-catenin signaling. Expansion cohorts focus on specific tumor types and Wnt pathway–driven malignancies.

ClinicalTrials.gov ID: NCT04851119

A Phase II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic Colorectal Cancer or Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic colorectal cancer (after 2-3 prior therapies) or hepatocellular carcinoma (after 1-2 prior therapies), who have good performance status and organ function. All patients receive enfortumab vedotin, an antibody-drug conjugate targeting Nectin-4 that delivers MMAE to tumor cells, administered intravenously every 28 days.

ClinicalTrials.gov ID: NCT06553885

A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with histologically confirmed colorectal adenocarcinoma and unresectable, liver-dominant metastatic disease who have progressed after at least two prior lines of systemic therapy, excluding those with prior Y-90/liver radiotherapy, extrahepatic metastases, dMMR/MSI-H/TMB-H tumors, or previous checkpoint inhibitor exposure. Patients receive intra-arterial yttrium-90 radioembolization, oral capecitabine, and intravenous atezolizumab (an anti–PD-L1 monoclonal antibody) to assess efficacy and safety of this multimodal approach.

ClinicalTrials.gov ID: NCT06555133

IIT2022-05-Sankar-BELIEVE: Phase II Study of Bevacizumab in Combination With Chemoimmunotherapy and Maintenance Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with treatment-naïve extensive-stage small cell lung cancer and radiographic liver metastases receive carboplatin/etoposide plus atezolizumab (anti–PD-L1) and bevacizumab (anti–VEGF) for 4 cycles, followed by maintenance atezolizumab/bevacizumab. Includes ECOG 0–2, measurable disease, and allows selected stable/asymptomatic brain metastases; excludes significant bleeding/thromboembolic risk, uncontrolled hypertension, recent major surgery, active autoimmune disease requiring therapy, and active HBV.

ClinicalTrials.gov ID: NCT05588388

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with well-differentiated (G1–2), SSTR-positive gastroenteropancreatic NETs with hepatic metastases undergo cytoreductive surgery followed within 90 days by standard PRRT with lutetium Lu 177 dotatate (a radiolabeled somatostatin analog delivering beta radiation to SSTR-expressing cells) every 8 weeks for up to 4 cycles. Excludes G3 disease, inoperable tumors >3 cm, prior PRRT, and uncontrolled comorbidities; outcomes include PFS, ORR by RECIST, safety, and SSTR-PET changes.

ClinicalTrials.gov ID: NCT06016855

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with hepatocellular carcinoma receiving SBRT who are at higher risk for post-radiation hepatic decompensation (e.g., ALBI ≥ −1.81, cumulative target ≥4 cm, or Child-Pugh ≥7) receive short-course oral prednisone starting before and during SBRT to reduce hepatic inflammation and radiation-induced liver toxicity. Prednisone is a corticosteroid (glucocorticoid receptor agonist) with anti-inflammatory/immunosuppressive effects; prior liver-directed therapy allowed if recovered.

ClinicalTrials.gov ID: NCT05901519

An Open Label Phase II Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with untreated, locally advanced/unresectable hepatocellular carcinoma (Child-Pugh A5–A6, ECOG 0–1) receive atezolizumab (PD-L1 inhibitor) plus bevacizumab (anti-VEGF) with the addition of memantine, an oral uncompetitive NMDA receptor antagonist being investigated to enhance antitumor activity. Key exclusions include Child-Pugh B/C, significant infections, recent major cardiovascular events, untreated/symptomatic CNS metastases or varices, prior memantine use, and mixed HCC histologies.

ClinicalTrials.gov ID: NCT06789757

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, locally advanced or metastatic HCC eligible for first-line therapy (ECOG 0–1, Child-Pugh A; exclusions include prior systemic therapy and high-risk portal hypertension) are randomized to atezolizumab/bevacizumab versus multiple immunotherapy-based combinations. Experimental arms include additions such as anti-TIGIT (tiragolumab), anti–IL-6R (tocilizumab), PPARα antagonist (TPST-1120/amezalpat), PD-1/LAG-3 bispecific (tobemstomig), masked anti–CTLA-4 (ADG126/muzastotug), anti-LILRB2 myeloid checkpoint (IO-108), or HIF-2α inhibitor (NKT2152/imdatifan), with adaptive crossover allowed after loss of benefit or toxicity.

ClinicalTrials.gov ID: NCT04524871

A Phase 1, Open-Label Study of ABSK-011 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with advanced solid tumors for dose escalation and a biomarker-selected expansion in FGF19-overexpressing BCLC B/C hepatocellular carcinoma (Child-Pugh A–B7), after or unsuitable for first-line systemic therapy. Patients receive oral irpagratinib (ABSK-011), a selective covalent FGFR4 inhibitor targeting FGF19–FGFR4 signaling, given QD or BID in 28-day cycles.

ClinicalTrials.gov ID: NCT04906434

Phase II Single Arm Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis (STRIDE in CP-B)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced HCC (BCLC B not eligible for locoregional therapy or BCLC C) and Child-Pugh B7–B8 cirrhosis, ECOG 0–1, no prior systemic therapy, including HBV/HCV with control. Patients receive the STRIDE regimen: a single priming dose of tremelimumab (CTLA-4 inhibitor) plus durvalumab maintenance (PD-L1 inhibitor) given every 4 weeks until progression or toxicity.

ClinicalTrials.gov ID: NCT06526104